Transgenomic Q1 Sales Down 69 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Molecular diagnostics firm Transgenomic today reported a sharp drop of 69 percent in first quarter sales reflecting the phasing of contracts due to client sample availability issues, but said that this effect is expected to be "transitory."

For the three-month period ended March 31, Transgenomics' net sales fell to $236,000 from $750,000 the year before. However, the company said it expects the effect causing the drop to be transitory.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Dec
06
Sponsored by
Natera

This webinar will discuss a partnership model for noninvasive prenatal testing that enabled LifeLabs Genetics, a genetic testing lab based in Toronto, Ontario, to implement NIPT in house.